biotech investment showcase topics on scientific, ... vcs and technology transfer offices. ... •...

For Booking details and registration fees, please email [email protected] or visit

www.biotechinvestment-showcase.com

BIOTECH INVESTMENT

SHOWCASE

&

START UP SLAM 2018

22-23 May 2018

London, UK

mailto:[email protected]

2018 Biotech Investor Showcase and Start-up Slam, 22nd- 23rd May 2018, London

The 2018 Biotech Investment showcase is the UK and Europe's most focussed and leading-edge funding,

investment and partnering forum in the biotech sector, hosting over 300 attendees. Leading VC funds,

pharma investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and

clinical companies as well as KOLs in the sector will be attending this one of a kind showcase event on

the 22nd & 23rd May 2018 in London. The event will help to identify the key technological and scientific

investment areas in the sector and will also offer a unique networking, partnering and business

development opportunity for those involved.

What does the showcase consist of?

Biotech Investment Conference Speakers, and Start up Slam Judging Faculty

Biotech Investment conference

programme and showcase

• An educational programme

with over 60 presentations,

postulating topics on scientific,

technological and investment

growth in the industry

• Over 50 biotech spinoffs,

early stage discovery and clinical

company product presentations

during the 2 days

• Two dedicated Startup Slam

Sessions and supported by a 20-

strong judging expert faculty

Networking opportunities &

scheduled business partnering

meetings

• Over 35 Scheduled business

partnering meetings

• Exhibition area with coffee

and lunch breaks

• Poster presentation

spotlights

• Pre-dinner reception and

networking drinks

Corporate Gala Dinner and

Awards

• Gala dinner and awards

ceremony featuring the best

scientist award categories

• Live polling throughout the

dinner on industry hot topics

• Supporting Cancer

Research UK through each event

evaluation form received

Start Up Slam

At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or

scientists like yourselves to present your new product and research in front of leading pharma and

biotech venture companies, VCs and Technology Transfer offices.

If you are developing an innovative product or technology in the following areas, please email

[email protected]

• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics

• Microbiome Discovery and Development

• Artificial Intelligence and Digital Health

• Immuno-Oncology and Immuno-Therapy

• Biomarkers/Precision Medicine/ Liquid Biopsy

Lori L. Badura,

EMD EMD Serono

Melanie Goward

Malvern Capital

Partners

Maciek Drozdz,

Johnson & Johnson Bent Jakobsen,

Immunocore Olga Krylova

Pfizer Mouad Lamrani

Menicon Co., Ltd

Paul-Peter Tak

GSK Timothy Herpin

Astra Zeneca Torsten Hoffmann

Silence

Therapeutics

Yiu-Lian Fong,

Johnson &

Johnson

Tony Hickson

Imperial Innovations

Ltd

Avi Spier

Novartis

John Haurum

F-star

Lothar Germeroth

Juno Therapeutics

Rakesh Dixit

Medimmune

Philip Arlen

Precision Biologics

Richard Sainson

Kymab

Kristin Wannerberger

Ferring

Biotech Investment Conference Speakers, and Start up Slam Judging Faculty includes:

• Paul-Peter Tak, Senior Vice President R&D Pipeline, Global Development Leader and Chief

Immunology Officer, GSK (Reserved)

• Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer

• Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment,

Medimmune

• Yiu-Lian Fong, Global Head Diagnostic Innovation, Research and Early Development, Johnson and

Johnson

• Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance

Management, EMD Serono

• Morten Lindow, Director, Innovation and Project Excellence, Roche

• Ro Wickramasinghe, Director of Oncology Evaluation, AstraZeneca

• Bent Jakobsen, Chief Scientific Officer, Immunocore

• Deborah A. O’Neil, Chief Executive & Scientific Officer, Novabiotics

• Christopher Roberts, Associate Director of Computational Biology, Biogen Idec (Reserved)

• Timothy Herpin, Vice President, Head of Transactions Business Development, Astra Zeneca

• Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A

• Bernhard Paetzold, Founder, S-Biomedic

• Mouad Lamrani, Director of R&D Innovation Center, Menicon Co., Ltd

• Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation

• Avi Spier, Director, NIBR BD&L, Search and Evaluation, CVM, GDC, CBT Chem-Bio, GNF Systems and

Microbiome, Novartis (Reserved)

• Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics

• Tommi Lehtonen, CEO, Blueprint Genetics

• Melanie Goward, Investment Director, Maven Capital Partners UK LLP

• Vijay Barathan, Life Science Partner, Catapult Ventures(Reserved)

• Tony Hickson, MD, Imperial Innovations Ltd

• Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells & Regenerative Medicine,

King's College London

• Patrice Garnier, CEO, AMABIOTICS

• Michael Fraser, VP University Relations, Queen's University(Reserved)

• Patrick Gillevet, Professor, Director, George Mason University, Director of the Microbiome Analysis

Center

• Lothar Germeroth, Senior Vice President, Managing Director, Juno Therapeutics GmbH

• Andreas Kungl, CEO, Antagonis

• Assaf Oron, Chief Business Officer, BioimX

• Pierre-Jean Ripoll, Director R&D France, Pharming Group

• Ron Alfa, VP of Discovery and Product, Recursion Pharmaceuticals

• Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.

• John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.

• Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.

• Fred Jacobs, CEO, TYG Oncology

• Imke Mulder, Research Director 4D Pharma Research Ltd

• Xavier Duportet, CEO, Eligo Bioscience

• Leonardo Rodrigues, Associate Director - Advanced Analytics , BERG

http://mbac.gmu.edu/mbac_wp/


DAY 1 – Stream 2

Microbiome Discovery and Development

➢ Machine learning and Data Analysis

➢ AI application in Pharma R&D

➢ High-throughput screening and AI

➢ Genomics, Big Data Analysis and Deep Learning

➢ AI in Drug Design and development

➢ AI and Precision medicine

➢ Translational informatics

➢ AI in Cloud computing and Big data

➢ Supporting Real World Evidence and E Health Support

➢ AI, Robotics and Machine Learning: leading data science and

machine learning

➢ Integrated Healthcare and Digital health

➢ Medical devices and digital healthcare solutions

DAY 1 – Stream 1

NGS/Genomics Technologies/dPCR/Microfluidics

bccghck

DAY 1 – Stream 3

Pharma Technologies, Artificial Intelligence, Medical Devices

and Digital Health

➢ Innovations of NGS in pharma: biomarker development,

precision medicine and clinical diagnostics

➢ NGS, genomics and clinical diagnostics in healthcare

➢ NGS Data Analysis & NGS Application Strategies

➢ Single Cell ‘Omics Analysis: Current and Emerging Tools

➢ Single Cell Analysis - Translation to Diagnostic and Therapeutic

Applications

➢ Single Cell Data Analysis & Advances in Microfluidic

Technologies

➢ Microbiome Discovery & Technologies

➢ Translational Science of the Microbiome

➢ Novel Genomic Technologies

➢ Next Generation Sequencing technologies

➢ Data Management in Microbiome Discovery

➢ Bacterial Pathogens and the Microbiome

➢ Small Molecule Microbiome Discovery

➢ Discovery and development of Microbiome Therapeutics in

Metabolic Disorders, Inflammatory Conditions, Women’s

Health, Dysbiosis

➢ Immune monitoring

➢ Clinical trial design and management

➢ Translational biomarkers

➢ Microbiome and Immuno-oncology

➢ Cancer Immunoassays for biomarker development

➢ Drug development partnerships

➢ Immuno-oncology Therapeutic Development

DAY 2 – Stream 1

Immuno-Oncology and Immuno- Therapy – Discovery and

Development

➢ Precision Medicine, Companion Diagnostics, Molecular

Diagnostics Development

➢ Innovations in Biomarkers Research, Assay

Development, Imaging, Data Integration Methods,

Bioinformatics, Trial Design

➢ Innovative Biology- NGS & Genomic Markers, Clinical

Testing and Diagnostics Development

➢ Genomic approaches in drug development

➢ Advances made in NGS techniques in liquid biopsy

➢ RNAseq NGS in biomarker benchmarking

BIOTECH INVESTMENT PROGRAMME AND SHOWCASE TOPICS

Day 2 - Stream 2

Proteins, Antibodies, Cell based Biotherapeutic Development

Gain insights and learn from over 60 expert speakers from pharmaceutical, biotech, academic, medical devices and

investment companies

Assessing the potential of artificial intelligence in drug discovery and development, machine learning and patient monitoring

Benefit from updates in Protein, Antibodies, Peptides and Cell based biotherapeutic development

Maximising your knowledge on the key discovery and development strategies in Immunotherapy, Immuno-oncology, Biologics

and Microbiome

Identifying the key technologies in accelerating the genomics revolution

Exploiting Biomarker technologies in clinical development, precision medicine and targeted therapy

Evaluating and overcoming the challenges of finding and funding innovation for Biotech spinoffs

Gaining insights from the Partnering and Licensing Innovations in the Pharma & Biotech industry

Attendee Benefits

Do not miss out on presenting on the speaker programme, featuring presentations by:

✓ Emerging university spin offs and entrepreneurial companies to access to interested VC funds and investors

✓ Academic researchers and technology transfer offices to present an IP or idea to funding and development partners

✓ Biotech companies to partner their products, form alliances and develop global financing contacts

For speaking opportunities, please email [email protected]

➢ Advancing to the clinic: antibody drug conjugates

➢ Innovative design and engineering approaches

➢ Fusion protein therapeutics

➢ New targets & new indications for protein biotherapeutics

➢ Accelerating antibody discovery & optimisation:

➢ Bispecific antibodies

➢ Monoclonal antibodies

➢ Antibody drug conjugates

DAY 2 – Stream 3

Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and

Clinical Development

08.00-08.30

Keynote Address- Addressing R&D Innovation in GSK

• Therapeutic areas in focus

• Partnering and open innovation

Paul-Peter Tak, Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer,

GSK

08.30-09.00

Panel Discussion - Artificial Intelligence and Digital Health

• Analysis of the Artificial Intelligence market: Drug Discovery and Development, Machines Learning and

Patient Monitoring

• Digital healthcare and integrated healthcare

Panellists: Vijay Barathan, Life Science Partner, Catapult Ventures(Reserved)

Leonardo Rodrigues, Associate Director - Advanced Analytics , BERG

Ron Alfa, VP of Discovery and Product, Recursion Pharmaceuticals

09.00-09.30

Panel Discussion - Accelerating Genomics Revolution

• Adoption of NGS

• Moving to single-cell biology

• Clinical Diagnostics

• cell-free DNA

• dPCR

• Microfluidics

Panellists: Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics

Michael Fraser, VP University Relations, Queen's University

Arbieva, Zarema, Director of Research Service Facility - Core Genomics Facility, CGF

EMD Serono

09.30-10.00

Panel Discussion - Innovation in the Pharma & Biotech – Partnership and Licensing

• Innovation in practice – how partnerships are formed in Pharma

• The latest drug research and development efforts, success and paths to commercialisation

Panellists:

Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer

10.00-10.30 Morning Refreshment Break

Stream 1: NGS/Genomic

Technologies/dPCR/ Microfluidics

Stream 2: Drug Discovery

and Development –

Microbiome, Immuno-

oncology, Oncology

Stream 3: Pharma IT,

Artificial Intelligence,

Medical Devices, and

Digital Health

Scheduled

Partnering

Meetings x8 and

Exhibition

10.30-10.45

Laura Roca-Alonso, Chief Business

Officer, Silence Therapeutics

Spinoffs and emerging

biotech company

presentation

AI and Variant Classification

In Rare Disorder Diagnostics

Tommi Lehtonen, CEO,

Blueprint Genetics

10.45-11.00

Spinoffs and emerging biotech

company presentation


biotech company

presentation


biotech company

presentation

11.00-11.15




biotech company

presentation


biotech company

presentation

11.15-11.30




biotech company

presentation


biotech company

presentation

11.30-11.45




biotech company

presentation


biotech company

presentation

11.45-12.00




biotech company

presentation


biotech company

presentation

DAY 1 Agenda At A Glance

12.00-12.15




biotech company

presentation


biotech company

presentation

12.15-12.30




biotech company

presentation


biotech company

presentation

12.30-13.30 Lunch

Stream 1: NGS/Genomic

Technologies/dPCR/ Microfluidics


and Development –

Microbiome

Stream 3: Pharma IT,

Artificial Intelligence,

Medical Devices, and

Digital Health

13.30 – 14.00

Single Cell Analysis - Translation

to Diagnostic and Therapeutic

Applications

Microbiome Discovery

and Development

Johan van Hylckama Vlieg,

Vice President Microbiome

and Health Innovation, Chr-

Hansen A/S (Invited)

Machine Learning and

Sequence Analysis As

Enablers Of RNA Drug

Discovery

Morten Lindow, Director,

Innovation and Project

Excellence, Roche

Scheduled

Partnering

Meetings x9 and

Exhibition

14.00 – 14.30

NGS Data Analysis & NGS

Application Strategies

Microbiome and Drug

Discovery Case Study

Patrice Garnier, CEO,

AMABIOTICS

AI and Precision medicine

Ron Alfa, VP of Discovery

and Product,

Recursion Pharmaceuticals

14.30 – 15.00

Collaborative Phenotyping at

King’s College London: HipSci and

the Stem Cell Hotel • Characterisation of a large panel of

Human Induced Pluripotent Stem

Cells (see www.hipsci.org)

• Integration of High Content imaging

with other datasets such as genomics,

transcriptomics, proteomics

• Opening of a collaborative

phenotyping space to internal and external scientists and technology

providers Davide Danovi, Director, HipSci

Cell Phenotyping, Centre for Stem

Cells & Regenerative Medicine,

King's College London

Microbiome and Drug

Discovery Case Study

Kristin Wannerberger,

Director R&D Alliance

Management, Ferring

International Center S.A

Machine Learning and

Data Analysis

Leonardo Rodrigues,

Associate Director -

Advanced Analytics , BERG

15.00 – 15.30

NGS, Genomics And Clinical

Diagnostics In Healthcare

Microbiome Drug

Development Case Study

Imke Mulder, Research

Director 4D Pharma

Research Ltd

Medical Devices And

Digital Healthcare

Solutions


http://www.hipsci.org/

15.30 – 16.00

Panel Discussion: Join our keynote

panellists as they address the

challenges of finding and funding

innovation for biotech spinoffs

• De-risking biotech projects in

the university environment

prior to spinout or licence – a

good or bad idea?

• The importance of patient

capital for early stage biotech

investments

• Other models of funding

therapeutic development

projects (e.g. Licensing funds

and project aggregators)

Tony Hickson, MD,

Imperial Innovations Ltd

Novel Approaches For

Microbiome Modulation

Addressing IBD, Cancer

And Acne

Assaf Oron, Chief Business

Officer, BioimX

Start Up Slam Event – 5 pitches

16.00-16.30 Afternoon Refreshments

16.30-17.00

Panel Discussion: Microbiome Discovery and Development

• What are the most successful microbiome trends with clear

therapeutic potential?

• What are the potential challenges of microbiome drug

development?

Moderator:

Avi Spier, Director, NIBR BD&L, Search and Evaluation, CVM,

GDC, CBT Chem-Bio, GNF Systems and Microbiome, Novartis

(reserved)

Panellists:

Maciek Drozdz, Principal of Venture Investments Johnson and

Johnson Development Corporation

Kristin Wannerberger, Director R&D Alliance Management,

Ferring International Center S.A

Bernhard Paetzold, Founder, S-Biomedic

Patrick Gillevet, Professor, Director, George Mason University,

Director of the Microbiome Analysis Center

Xavier Duportet, CEO, Eligo Bioscience

Start Up Slam Event – 5 pitches

17.00-17.30

Innovations of NGS In Pharma: Biomarker Development,

Precision Medicine And Clinical Diagnostics

17.30-18.00

Single Cell Data Analysis & Advances in Microfluidic

Technologies

Christopher Roberts, Associate Director of Computational

Biology, Biogen Idec (Reserved)

18.00 – 18.30

AI in Cloud computing and Big data

18.30-19.45 Drinks Reception

19.45-21.00 Sponsored Awards Dinner

END OF DAY ONE


08.00-08.30

Keynote Address – Biomarker Clinical Market Development, Companion Diagnostics Development

And Targeted Therapy

08.30-09.00

Panel Discussion - Accelerating Antibody Discovery & Optimisation:

o Bispecific antibodies

o Monoclonal antibodies

o Antibody drug conjugates

Panellists:

Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.

09.00-09.30

Panel Discussion - Precision Medicine/Liquid Biopsy/Targeted Patient Treatment

Panellists:

Yiu-Lian Fong, Global Head Diagnostic Innovation, Research and Early Development, Johnson and Johnson

Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management Healthcare Business, EMD Serono

Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.

09.30-10.00

Special Address: Updates on Immuno-Oncology Discovery and Development Trends

Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment,

Medimmune

10.00-10.30 Morning Refreshment Break


and Development -

Immuno-Oncology and

Immuno-Therapy

Stream 2: Proteins,

Antibodies, Cell

Therapeutic

Development

Stream 3:

Biomarkers/Precision

Medicine/Liquid Biopsy in

Drug Development and

Clinical Trials

Scheduled Partnering

Meetings x8 and

Exhibition

10.30-10.45

Fred Jacobs, CEO, TYG

Oncology(TBC)


biotech company

presentation


biotech company

presentation

10.45-11.00


biotech company

presentation


biotech company

presentation


biotech company

presentation

11.00-11.15


biotech company

presentation


biotech company

presentation


biotech company

presentation

11.15-11.30


biotech company

presentation


biotech company

presentation


biotech company

presentation

11.30-11.45


biotech company

presentation


biotech company

presentation


biotech company

presentation

11.45-12.00


biotech company

presentation


biotech company

presentation


biotech company

presentation

12.00-12.30

Panel Discussion – Market Outlook for Immuno-oncology investment

Recent Deal Trends In Immuno-Oncology

• From the Biotech perspective: funding environment, partnerships and exits

• From the Pharma side: deal trends and emerging innovation

• Strategies and tactics for combination therapies

Moderator:

Timothy Herpin, Vice President, Head of Transactions, Business Development,

AstraZeneca

Panellists: John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.

Ro Wickramasinghe, Director of Oncology Evaluation, Astra Zeneca


12.30-13.30 Lunch


and Development -

Immuno-Oncology and

Immuno-Therapy

Stream 2: Proteins,

Antibodies, Cell

Therapeutic

Development

Stream 3: Clinical

Development, Biomarkers,

Precision Medicine

Scheduled Partnering

Meetings x9 and

Exhibition

13.30-14.00

Immuno-oncology

Therapeutic Development

Richard C.A. Sainson,

Director in Pharmacology

and Translational Sciences,

Kymab

Antibody Engineering,

Design & Development

Approaches

Biomarkers And Liquid

Biopsy

Jun Huang, Associate

Director, R&D and BioPharma

Solutions, Admera Health,

LLC (Invited)

14.00 – 14.30

Immuno-oncology Clinical

Development - ImmTACs

Bent Jakobsen, Chief

Scientific Officer, Immunocore

Recombinant Protein

Therapeutics

Pierre-Jean Ripoll,

Director R&D France,

Pharming Group

Precision Medicine,

Companion Diagnostics,

Molecular Diagnostics

Development

14.30 – 15.00

Car T Cells For The

Treatment Of Cancer

• Status of clinical trials

• Manufacturing of Car T

cells

• Future of Car T cell

treatments

Lothar Germeroth, Senior

Vice President Juno

Therapeutics Inc., Managing

Director Juno Therapeutics

GmbH

GAGbodies: a new class

of biotherapeutics

targeting glycans in

immuno-oncological indications

Andreas Kungl, CEO,

Antagonis

Precision Medicine And The

Role of Biomarkers in

Clinical Development

Philip M. Arlen, President &

Chief Executive Officer,

Precision Biologics, Inc.

15.00 – 15.30

Cancer Immunoassays for

Biomarker Development

Cutting Edge

Technologies For

Antibody Discovery

Data Integration Methods

15.30 – 16.00 Afternoon Refreshments

16.00-16.30

Clinical Trial Design And

Management

Peptide Discovery and

Development

Innovative Biology- NGS &

Genomic Markers, Clinical

Testing and Diagnostics

Development

16.30-18.30 Start Up Slam x 5 Pitches

END OF SHOWCASE

Featured Event at the Showcase : Start Up Slam

At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or

scientists like yourselves to present your new product and research in front of leading pharma and biotech

venture companies, VCs and Technology Transfer offices. If you are developing an innovative product or

technology in the following areas, please email [email protected]

• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics

• Microbiome Discovery and Development

• Pharma Technologies, Artificial Intelligence, Medical Devices and Digital Health

• Immuno-Oncology and Immuno-Therapy Drug Discovery and Development

• Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and Clinical Development

• Proteins, Antibodies, Cell Therapeutic Development

BOOKING FORM HOW TO REGISTER:

FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]

Please complete fully and clearly. Please photocopy for additional delegates Title: …………………………… Forename: ………………………………………………….. Surname: …………………………………………………... Company/Organisation: …………………………………………………………………………………………………………………………………………. Job Title: …………………………………………………………………………………………………………………………………………………………... Address: ……………………………………………………………………………………………………………………………………………………………. Postcode: …………………………... Country: …………………………... Direct Telephone: ………………………………... Mobile: …………….…………….. Switchboard: ……………………….. Fax: ……………………….. Email: ……………………………………………………………………………………………………………………………………………………………….. Signature: ………………………………………………. Date: ……………………………………………………..

Number of delegates:

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: /

Expiry Date: /

Security code:

Cardholders name ………………………………………...

Signature: …………………………………………………. Date: ……………………………………….

PLEASE INVOICE ME:

Invoice Address (if different from above) ……………………………………………………………………… ……………………………………………………………………… ……………………………………………………………………... PO Number (if applicable) ………………………………………. * Please note there is a £50 plus VAT handling charge for payment via invoice * All card payments will be subject to a 3% bank charge or 4% AMEX charge * Payment to be made within 30 days of invoice

Registration Fees

Delegate Details

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) REGISTRATION AND PARTNERING ACCESS (FULL PASS) • Full access to the 1-2-1 networking portal pre-event • Up to 17 Meetings per day (34 meetings over 2 days) • 1x full conference pass

Academic Spinoffs, Biotech spinoffs, TTOs: £950+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £2450+VAT POSTER PRESENTATION • 1x A0 portrait poster display in exhibition hall (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs:

£150+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £250+VAT SPEAKER PRESENTATION • 15 Minute presentation platform in conference room (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs: £250+VAT

VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors, Solution Providers: £1000+VAT EXHIBITION • 2x2m table-top in main Exhibition Hall (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs:

£500+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £1000+VAT

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected] www.biotechinvestment-showcase.com

Terms & Conditions of Booking

I agree to the terms and conditions (Please refer to page 2 for the terms and conditions)

To obtain information on our full sponsorship opportunities, please contact [email protected]

Sponsorship Opportunities


1. Definitions In these terms and conditions, the following terms have the following meanings: - “Contract Price” The total cost payable for the Package as shown on the official booking form “Delegate/Sponsor” Any person who has been invited by the Organisers to attend the showcase, start up slam and partnering meetings OR Any company or person who has purchased a package or any agent representative or employee of such company or person “Event” named in the Terms and Conditions Title above "Meeting Area" The meeting area/exhibition space designated for the Sponsor/Exhibitor at the Event “Organisers” Oxford Global Marketing Limited “Package” The accommodation, area for meetings and conference sessions in a hotel venue where the Event will take place in-cluding meals but not beverages unless specified by the Organiser. 2. Law These terms shall be construed in accordance with English law and subject to the exclusive jurisdiction of the English courts. 3. Application for Packages Applications must be made on the Organiser’s official booking form, which must be completed in full. The Organisers may accept applications in writing, by email or facsimile, or accept a deposit payment in lieu of written application at their sole discretion, and on the understanding that these terms and conditions apply to any application and supersede any terms and conditions of the Delegate/Sponsor. Any alterations of these terms and conditions cannot be accepted without the prior written consent of a direc-tor of the Organiser. 4. Payment The Delegate/Sponsor shall pay the contract price in accordance with the dates set out in the official booking form. If any of the above payments shall be 30 days in arrears whether demanded or not, the contract may at any time thereafter be terminated forthwith by the organisers by notice in writing to these parties. Upon termination all instalments paid shall be forfeited and the balance shall become immediately payable. Such termination shall not prejudice any rights or claims by the Organisers against these parties in respect of any prior breach. 5. Contract and Termination On the acceptance of the official booking form by the Organisers, a contract relating to the package purchased by the Delegate/Sponsor will exist between these parties and the Organisers as set out in these terms and conditions. In case of non payment of any sum due from these parties whether legally demanded or not, or of the breach, or non-observance, by these parties of any of these terms and conditions, or any regulations to be observed by these parties, the Organisers shall have the right to terminate the contract and to remove and exclude these parties from the Event without prejudice to the right to recover all sums payable by these parties and all other claims against it, and any loss of damage sustained by the Organisers. 6. Withdrawal or Cancellation In the event of withdrawal or cancellation, the following amounts shall become immediately payable: More than 6 months prior to the event 35% cancellation fee Between 6 and 3 months prior 75% cancellation fee Less than 3 months prior to the event full cancellation fee Any notification of withdrawal or cancellation must be in writing and sent to the Organisers by recorded delivery. Cancellation will be deemed to have occurred when written notification has been received by the Organisers. 7. Occupation of Meeting Area The Delegate/Sponsor (subject to contracted package) must occupy their allocated Meeting Area by the Event opening time on the first day of the Event. Failing to do so will be deemed a cancellation of Package, in which case the terms and conditions relat-ing to withdrawal or cancellation will apply, and the Package may be offered to another Delegate/Sponsor. 8. Bankruptcy In the event of bankruptcy, liquidation, having an administrator or receiver appointed, or entering into a voluntary arrangement with its creditors; the Delegate/Sponsor’s contract may be terminated at the option of the Organisers and the full contract price will be due and payable forthwith. 9. Prohibition of Transfer A Delegate/Sponsor may not assign, sublet or share possession of, or grant licenses in respect of the whole or any part of the Package nor may any cards, advertisements, or printed matter of firms who are not bona fide Delegate/Sponsor’s be exhibited in or distributed from any area. This does not apply to firms which are subsidiaries, agents or principals of the Solution Provider and which are duly listed on the official application form at the time of booking.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]


10. Postponement or Abandonment The Delegate/Sponsor shall not have any claim against the Organisers in respect of any loss or damage consequent upon the failure for whatever reason to hold any part of the Event or if the hotel venue at which the Event is scheduled to take place be-comes wholly or partially unavailable for the holding of the Event. If, by the re-arrangement or postponement of the period of the Event, or by substitution of another hotel venue for the holding of the Event, or any other reasonable action, the Event can take place, the contract shall remain in force. If the Organisers abandon the Event other than by reason of events or circumstances beyond its reasonable control, the Organisers will reimburse the Contract Price. If the Event is abandoned by the Organisers by reason of events or circumstances beyond it’s reasonable control, the Organiser will reschedule the Event (to be held within 12 months of the original event) but no reimbursement will be made by the Organiser and the Delegate/Sponsor will remain liable to pay the Contract Price. 11. Liability Save in the case of death or personal injury caused by the Organisers' negligence, the Organisers are not responsible for the health & safety of any meeting or conference or any property of the attendees or any third party, or for any loss or damage sus-tained by these parties or any third party, in each case for any reason whatsoever. Delegates/Sponsors should have in place their own insurance to cover all such liabilities and risks. 12. Event Promotional Materials Only the signage provided by the Organisers will be used by the Delegate/Sponsor. The Organisers will notify the Delegate/Sponsor of the nature of available meeting facilities and of promotional material e.g. display stands and brochures that they may display. The Organisers reserve the right (without being required to give notice) to alter the layout of any meeting floor plan at any time and to relocate these parties to another area. 13. Information and Copyright Information supplied by the Organisers in relation to any event is accurate to the best of their knowledge and belief, but shall not constitute any warranty or representation by the Organisers and any inaccuracy or mistake in such information or omission from it shall not permit the Delegate/Sponsor to cancel a confirmed booking. All information and data relating to the Event, which is supplied by the Organisers to the Delegate/Sponsor is the copyright of the Organisers and cannot be passed on to any third party for any purpose. The Organiser processes information about each Delegate/Sponsor in accordance with the Organiser's privacy policy, a copy of which is available on our website or by written request. By submitting information to the Organiser, the Delegate/Sponsor con-sents to such processing and warrants that all data provided is accurate 14. Substitution The Delegate/Sponsor may substitute a representative up to 3 weeks before the event provided that this is conveyed via email to the Organiser and also by completing a new on-line application form and stating in the relevant box on the form the name of the person s/he is replacing. The replacement Delegate/Sponsor will take over the partnering meetings agreed by the original party, although these can be cancelled if the meetings are no longer relevant.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]

biotech investment showcase topics on scientific, ... vcs and technology transfer offices. ... •...

Documents